Stockreport

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Approval is based on the pivotal Phase 2 TRUST-I study, demonstrating taletrectinib's durable responses and prolonged progression-free survival NEW YORK, January 06, [Read more]